Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047172 · ClinicalTrials.gov registry record · Phase 3
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
A Phase 3 study of Stroke and Intracranial Arteriosclerosis, sponsored by University of Florida.
- Active
- Registry status
- Phase 3
- Development phase
- 1,683
- Enrollment target
- 20
- Study locations
NCT05047172 is a Phase 3 study of Stroke and Intracranial Arteriosclerosis that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 1,683 participants, below the 12,013-participant average among 454 other Stroke trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05047172, a Phase 3 study of Stroke and Intracranial Arteriosclerosis, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,683 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Conditions Studied
Interventions
- DRUG Ticagrelor + Aspirin
- DRUG Rivaroxaban + Aspirin
- DRUG Clopidogrel + Aspirin
- OTHER Risk Factor Management
Study Locations (20)
California
- Mercy San Juan Medical Center - Carmichael
- The Neuron Clinic - Chula Vista - Chula Vista
- Kaiser Permanente Fontana Medical Center - Fontana
- Long Beach Memorial Medical Center - Long Beach
- Los Alamitos Medical Center - Los Alamitos
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles, CA - Los Angeles
- UC Irvine Medical Center - Orange
- UC Davis Medical Center - Sacramento
- Salinas Valley Memorial Hospital - Salinas
- UCSD Medical Center - Hillcrest Hospital - San Diego
- Providence Little Company of Mary Medical Center Torrance - Torrance
Alabama
- University of Alabama Hospital - Birmingham
- University of South Alabama University Hospital - Mobile
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Phoenix
Colorado
- University of Colorado Hospital - Aurora
- St. Mary's Medical Center - Grand Junction
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,683 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047172
The ClinicalTrials.gov registry entry for NCT05047172 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,683 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,013-participant average among 454 other Stroke trials with a reported enrollment target (86% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 4 interventions - of which Ticagrelor + Aspirin is the first listed.
NCT05047172 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05047172 about?
NCT05047172 is a clinical study titled "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis". The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
What is the current status of trial NCT05047172?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,683 participants. The study started on 2022-08-02. Estimated completion is 2028-05-31.
What conditions does trial NCT05047172 study?
This clinical trial studies the following conditions: Stroke, Intracranial Arteriosclerosis.
What interventions are being tested in trial NCT05047172?
The interventions under investigation include: Ticagrelor + Aspirin (DRUG), Rivaroxaban + Aspirin (DRUG), Clopidogrel + Aspirin (DRUG), Risk Factor Management (OTHER).
Who is sponsoring clinical trial NCT05047172?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05047172 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Locomotor Experience Applied Post Stroke Trial
COMPLETED · Phase 3
-
Vitamin Therapy for Prevention of Stroke
COMPLETED · Phase 3
-
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
COMPLETED · Phase 3
-
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
COMPLETED · Phase 3
-
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.